AU696235C - Anti-GP39 antibodies and uses therefor - Google Patents

Anti-GP39 antibodies and uses therefor

Info

Publication number
AU696235C
AU696235C AU76429/94A AU7642994A AU696235C AU 696235 C AU696235 C AU 696235C AU 76429/94 A AU76429/94 A AU 76429/94A AU 7642994 A AU7642994 A AU 7642994A AU 696235 C AU696235 C AU 696235C
Authority
AU
Australia
Prior art keywords
anti
uses therefor
gp39 antibodies
gp39
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76429/94A
Other versions
AU696235B2 (en
AU7642994A (en
Inventor
Alejandro Aruffo
Teresa M Foy
Jeffrey A. Ledbetter
Randolph J Noelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Bristol Myers Squibb Co
Original Assignee
Bristol-Myers Squibb Company
Trustees Of Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US232929 priority Critical
Priority to US11625593A priority
Priority to US116255 priority
Priority to US08/232,929 priority patent/US5869049A/en
Application filed by Bristol-Myers Squibb Company, Trustees Of Dartmouth College filed Critical Bristol-Myers Squibb Company
Priority to PCT/US1994/009871 priority patent/WO1995006666A1/en
Publication of AU7642994A publication Critical patent/AU7642994A/en
Application granted granted Critical
Publication of AU696235C publication Critical patent/AU696235C/en
Publication of AU696235B2 publication Critical patent/AU696235B2/en
Anticipated expiration legal-status Critical
Application status is Ceased legal-status Critical

Links

AU76429/94A 1993-09-02 1994-09-02 Anti-GP39 antibodies and uses therefor Ceased AU696235B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US232929 1981-02-09
US11625593A true 1993-09-02 1993-09-02
US116255 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009871 WO1995006666A1 (en) 1993-09-02 1994-09-02 Anti-gp39 antibodies and uses therefor

Publications (3)

Publication Number Publication Date
AU7642994A AU7642994A (en) 1995-03-22
AU696235C true AU696235C (en) 1998-01-29
AU696235B2 AU696235B2 (en) 1998-09-03

Family

ID=26814047

Family Applications (2)

Application Number Title Priority Date Filing Date
AU76429/94A Ceased AU696235B2 (en) 1993-09-02 1994-09-02 Anti-GP39 antibodies and uses therefor
AU35183/97A Ceased AU707110B2 (en) 1993-09-02 1997-08-21 Methods for inducing antigen-specific T cell tolerance

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU35183/97A Ceased AU707110B2 (en) 1993-09-02 1997-08-21 Methods for inducing antigen-specific T cell tolerance

Country Status (17)

Country Link
US (5) US5747037A (en)
EP (2) EP0721469B1 (en)
JP (3) JP3007977B2 (en)
CN (2) CN1127351C (en)
AT (2) AT167062T (en)
AU (2) AU696235B2 (en)
DE (4) DE69411025D1 (en)
DK (2) DK0721346T3 (en)
ES (2) ES2143553T3 (en)
FI (2) FI105528B (en)
GR (2) GR3027658T3 (en)
HU (2) HU220296B (en)
IL (1) IL110855A (en)
NO (2) NO321036B1 (en)
NZ (3) NZ549136A (en)
PT (1) PT721469E (en)
WO (2) WO1995006666A1 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
DE69411025D1 (en) * 1993-09-02 1998-07-16 Dartmouth College A method for stimulating antigen-specific T cell tolerance
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
JPH08239324A (en) * 1995-03-03 1996-09-17 Fusanori Hamashima Immunosuppressive medicine
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
DE69713499D1 (en) * 1996-03-20 2002-07-25 Bristol Myers Squibb Co A method for inhibiting the immune response by blocking the gp39 / CD40 and CTLA4 / CD28 / B7 route and composition to their use
DE19634159C1 (en) * 1996-08-23 1997-09-25 Gsf Forschungszentrum Umwelt Hybrid cells prepared by fusing malignant B cells with hybridoma that expresses antibodies
WO1998008541A1 (en) * 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
IL130785D0 (en) * 1997-01-10 2001-01-28 Biogen Inc Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
CA2356779C (en) 1998-12-14 2012-03-13 Genetics Institute, Inc. Cytokine receptor chain
WO2000038708A1 (en) * 1998-12-24 2000-07-06 Phairson Medical Inc. Treatment and prevention of immune rejection reactions
WO2000072882A1 (en) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Preventives for idiopathic thrombocytopenic purpura
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1262194A4 (en) * 2000-03-06 2003-05-07 Eisai Co Ltd Remedies and preventives for antiphospholipid antibody syndrome
AU5161201A (en) 2000-04-14 2001-10-30 Millennium Pharm Inc Roles of jak/stat family members in tolerance induction
EP1286692A4 (en) * 2000-04-25 2004-11-17 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
JP2003533488A (en) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド Compositions and methods for achieving immunosuppression
JP2003535592A (en) * 2000-06-06 2003-12-02 アイデック ファーマスーティカルズ コーポレイション Non agonist antibody against human gp39, compositions containing, and therapeutic uses thereof
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
MXPA02012603A (en) 2000-07-03 2003-05-14 Squibb Bristol Myers Co Methods for treating rheumatic diseases using a soluble ctla4 molecule.
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002040050A1 (en) * 2000-11-14 2002-05-23 The University Of Louisville Research Foundation, Inc. Non-lethal methods for conditioning a recipient for bone marrow transplantation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
PT1517921E (en) * 2002-06-28 2006-09-29 Domantis Ltd Differently specified ligands with semi-life in the increased serum
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2003220820A1 (en) * 2002-04-03 2003-10-27 Eisai Co., Ltd. Remedies for pemphigus containing cd40l antagonist as the active ingredient
CN1326878C (en) * 2003-04-29 2007-07-18 中国抗体制药有限公司 Anti human non-Hodgkin's lymphoma chimeric antibody and its derivative and application
DE602004029252D1 (en) * 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and their uses
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
ES2533084T3 (en) 2003-12-23 2015-04-07 Genentech, Inc. Cancer treatment with novel anti-IL 13 monoclonal antibodies
AR049390A1 (en) * 2004-06-09 2006-07-26 Wyeth Corp Antibodies against human interleukin-13 and uses thereof
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154 antibodies
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5805358B2 (en) * 2005-02-02 2015-11-04 ブルース・ミルネ・ホール Activated to the specific antigen cd4 +, cd25 + t cells
CN100423775C (en) 2005-04-15 2008-10-08 中国农业科学院兰州兽医研究所 Inactivated vaccine of cow chlamydia, its preparation and inspection method
CA2608750A1 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
RU2423381C2 (en) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Decreasing b-cell count with using cd37-specific and cd20-specific binding molecules
ES2363891T3 (en) * 2006-03-20 2011-08-18 The Regents Of The University Of California Antibodies to the antigen of prostate stem cells (PSCA) genetically modified for targeting to cancer.
RU2487888C2 (en) * 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Single-chain multivalent binding proteins with effector function
WO2008014555A1 (en) 2006-08-02 2008-02-07 Newsouth Innovations Pty Limited Method of identifying cd4+cd25+ t cells activated to an antigen which express cd8
JP2010527916A (en) * 2007-04-23 2010-08-19 ワイス・エルエルシー Il-13 method of treating related disorders and compositions and methods of monitoring the therapeutic
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2052848A1 (en) 2007-10-27 2009-04-29 Joint Solar Silicon GmbH & Co. KG Manufacture of moulded blanks from high-grade silicon
SI2132228T1 (en) * 2008-04-11 2011-10-28 Emergent Product Dev Seatle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CN102388063B (en) 2009-02-10 2016-04-20 纽约哥伦比亚大学理事会 5c8Mab and regulatory CD8 + T cells directly establish lasting induction and use of specific transplantation tolerance
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
BR112016004413A2 (en) 2013-09-13 2017-10-17 Genentech Inc composition, antibody preparation and purification method for a recombinant polypeptide and treating a disorder
KR20160054559A (en) 2013-09-13 2016-05-16 제넨테크, 인크. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
AT274055T (en) * 1991-10-25 2004-09-15 Immunex Corp new cytokine
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
KR100398819B1 (en) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 Pharmaceutical composition comprising a gp39 antagonist
DE69411025D1 (en) * 1993-09-02 1998-07-16 Dartmouth College A method for stimulating antigen-specific T cell tolerance
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Similar Documents

Publication Publication Date Title
AU684585B2 (en) Interrupted-flow assay device
AU676713B2 (en) Fuel composition
AU697440B2 (en) Polypeptide with reduced allergenicity
EP0648228B8 (en) Bnp antibody and immunoassay using it
AU673460B2 (en) Sifting device
AU684992B2 (en) Hapten-marked peptides
AU690093B2 (en) New protein from urine named component B
AU684570B2 (en) Ultramulsions
AU695850B2 (en) Poly-beta -1-4-N-acetylglucosamine
AU3600193A (en) Nucleozymes
AU3391693A (en) Sulfonamidocarboxamide
AU6281494A (en) Charging system
AU6665794A (en) Balanced modulator-transmitter
AU7106694A (en) Automated highway system
AU6231894A (en) Waterproof oversock
AU1321895A (en) Binding assay
AU7072694A (en) Substituted aryl-keto-enolic heterocycles
AU7481396A (en) Gel-filled closure
PL180157B1 (en) Humanised antibodies and their application
HU9503312D0 (en) Modified factor vii
AU6207794A (en) Mannose or xylose based positive selection
AU1118095A (en) Micropump
AU6851694A (en) Polyester composition
AU2139295A (en) Monoclonal antibodies recognizing tie-receptor and their use
AU6072994A (en) Tri-carbamate-functional crosslinking agents